Evidence map›Paper›PMID 41199376›Full record

ArticleGenes and environment : the official journal of the Japanese Environmental Mutagen Society2025

Mitomycin C-induced DNA double-strand breaks are enhanced by catalytical inactivation of DNA polymerase κ in mice.

Naoko A Wada, Akira Takeiri, Shigeki Motoyama, Kaori Matsuzaki, Kenji Tanaka, Saori Matsuo, Etsuko Fujii-Takeiri, Hiromi Tateishi, Kaoru Matsumoto, Naoko Niimi and 7 more

Abstract read
In one paragraph

Article in Genes and environment : the official journal of the Japanese Environmental Mutagen Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Naoko A WadaResearch Division, Chugai Life Science Park Yokohama, Chugai Pharmaceutical Co., Ltd., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Akira TakeiriTranslational Research Division, Chugai Life Science Park Yokohama, Chugai Pharmaceutical Co., Ltd., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan. takeiriakr@chugai-pharm.co.jp.
Shigeki MotoyamaResearch Division, Chugai Life Science Park Yokohama, Chugai Pharmaceutical Co., Ltd., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Kaori MatsuzakiTranslational Research Division, Chugai Life Science Park Yokohama, Chugai Pharmaceutical Co., Ltd., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Kenji TanakaTranslational Research Division, Chugai Life Science Park Yokohama, Chugai Pharmaceutical Co., Ltd., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Saori MatsuoTranslational Research Division, Chugai Life Science Park Yokohama, Chugai Pharmaceutical Co., Ltd., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Etsuko Fujii-TakeiriTranslational Research Division, Chugai Life Science Park Yokohama, Chugai Pharmaceutical Co., Ltd., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Hiromi TateishiChugai Research Institute for Medical Science, Inc., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Kaoru MatsumotoChugai Research Institute for Medical Science, Inc., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Naoko NiimiDiabetic Neuropathy Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-Ku, Tokyo, 156-8506, Japan.
Akira SassaDepartment of Biology, Graduate School of Science, Chiba University, 1-33 Yayoi-Cho, Inage-Ku, Chiba, Chiba, 263-8522, Japan.
Petr GrúzDivision of Genome Safety Science, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-Ku, Kawasaki, Kanagawa, 210-9501, Japan.
Kenichi MasumuraDivision of Risk Assessment, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-Ku, Kawasaki, Kanagawa, 210-9501, Japan.
Masayuki MishimaDivision of Genome Safety Science, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-Ku, Kawasaki, Kanagawa, 210-9501, Japan.
Kou-Ichi JishageChugai Research Institute for Medical Science, Inc., 216 Totsuka-Cho, Totsuka-Ku, Yokohama, Kanagawa, 244-8602, Japan.
Kei-Ichi SugiyamaDivision of Genome Safety Science, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-Ku, Kawasaki, Kanagawa, 210-9501, Japan.
Takehiko NohmiDivision of Pathology, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-Ku, Kawasaki, Kanagawa, 210-9501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDNA polymerase κ (Polk), a member of Y-family DNA polymerases, plays an important role in translesion DNA synthesis (TLS), allowing DNA replication forks to bypass DNA damage or DNA adducts to continue daughter strand synthesis. Polk is also believed to contribute to the replication-independent repair of DNA lesions such as cross-links. TLS circumvents stalls of DNA replication and promotes gap filling in DNA repair which would otherwise result in DNA double-strand breaks (DSBs) and cell death. Mitomycin C (MMC) is a widely used chemotherapeutic drug which generates DNA cross-links and induces DSBs. To clarify how Polk contributes to the prevention of MMC-induced DSB in various organs or tissues, immunohistochemical staining of γH2AX was conducted in catalytically inactivated Polk knock-in (Polk KI) mice and Polk wild-type (Polk

resultsThe γH2AX induction by MMC was enhanced by inactivation of Polk across many organs or tissues to varying degrees. Obvious enhancement was observed in liver, bladder, adrenal cortex, thyroid, and spermatids, whereas less enhancement was shown in brain and retina. The results suggest that Polk plays a role in preventing DSBs caused by MMC in most organs or tissues. Elevated DSB frequencies were observed in both proliferative cells, such as bladder epithelium cells, and less or slowly proliferative cells, such as hepatocytes. Increased DSB levels in inactivated Polk KI mice relative to Polk

conclusionPolk plays a systemic role in mitigating MMC-induced DSBs, likely through both DNA replication-dependent and -independent mechanisms. Furthermore, Polk appears to protect against DSBs caused by endogenous mutagens in some organs such as the adrenal cortex, prostate, and retina.

Indexed as

DNA double-strand breaksDNA polymerase κgpt delta miceMitomycin CTranslesion DNA synthesis

Identifiers

PMID41199376
PMCPMC12590760

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.